LaBrosse Nicole 4

What Happened
Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics (HALO), had restricted stock units (RSUs) and performance stock units (PSUs) vest and settle into 23,773 shares on February 16, 2026. The awards converted at $0.00 per share (no cash exercise price). To cover tax withholding obligations, 12,894 of those shares were surrendered to the issuer at an effective withholding price of $79.44 per share, totaling approximately $1,024,300. Net shares delivered to LaBrosse were 10,879.

Key Details

• Transaction date: February 16, 2026; Form 4 filed Feb 17, 2026 (timely).
• Awards settled: 5,093 + 5,329 + 13,351 = 23,773 shares (code M: exercise/conversion of derivative representing vesting).
• Shares withheld for taxes: 2,747 + 2,874 + 7,273 = 12,894 shares (code F), withheld at $79.44/share = $1,024,300 (approx).
• Net shares received: 10,879.
• Footnotes: F4 = vesting/settlement of RSUs; F5 = vesting/settlement of PSUs; F1–F3 explain shares withheld to satisfy tax withholding.
• Filing appears timely; no 10b5-1 or late-filing notation in the report.

Context
This was an award vesting/settlement event (not an open-market buy or sale). The share surrender to cover tax obligations is a routine, non-market sale mechanism (cashless/stock-withholding). Such transactions reflect compensation vesting rather than an executive-initiated sale or purchase decision.